Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AACB vs NCNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AACB Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 6–0 Matrix Metrics)

AACB Overall Winner 6-Pillar Tally: AACB 3 – 0 NCNA (3 Tie) Matrix Metrics: AACB 6 – 0 NCNA

As of Nov 16, 2026, AACB (AACB) is the stronger overall head-to-head candidate over NuCana plc American Depositary Share (NCNA) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AACB carries a Unified Composite Score of 55.3/100 (HOLD) at $10.59 (N/M Forward P/E, 0.0% operating margin), whereas NCNA carries 43.2/100 (HOLD) at $0.86 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: AACB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 61.7); meanwhile NCNA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AACB vs NCNA
AACB US Equity Head-to-Head Winner
AACB
Institutional Equity
$10.59
+0.09% 1D
Market Cap $292.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.02β · 3% Vol
Unified Composite Score
55.3 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 62
RSI-14: 61.7 · SMA20: $10.55 · SMA50: $10.53
NCNA NASDAQ
NuCana plc American Depositary Share
Pharmaceutical Preparations
$0.86
-7.46% 1D
Market Cap $3.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.49β · 59% Vol
Unified Composite Score
43.2 / 100 HOLD
Tech 27.0 Fund 46.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.4%), weak momentum, RSI 31
RSI-14: 31.5 · SMA20: $0.98 · SMA50: $1.12

6-Pillar Scorecard Institutional Category Breakdown (AACB 3 – 0 NCNA)

Columns: Metric · AACB · NCNA
1. Valuation Multiples AACB
Forward P/E N/M N/M
Trailing P/E 62.2x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) -73.2% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $292.8M $3.9M
3. Profitability & Quality AACB
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) 0.0% -70.3%
4. Balance Sheet & Cash Flow AACB
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage 0.0% ROE $7.83 Book/Sh · -70.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Shell Companies Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AACB (6) vs NCNA (0)
Institutional Metric AACB NCNA Criterion Row Edge
Market Capitalization
Scale
$292.8M $3.9M Larger Scale AACB
Trailing P/E Ratio
Valuation
62.2x N/M Lower Multiple AACB
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
0.0% -70.3% Higher ROE AACB
52-Week Range Position
Momentum
98% ($10–$11) 0% ($1–$5) Stronger Trend AACB
Beta / 30D Volatility
Risk Regime
0.02β · 3% Vol 1.49β · 59% Vol Lower Realized Risk AACB
Unified Institutional Score
Composite Signal
55.3 / 100 (HOLD) 43.2 / 100 (HOLD) Higher Composite AACB
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (0.0% ROE) N/A ($7.83 Book/Sh · -70.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NCNA +17.46 pp
AACB: +0.86% · NCNA: +18.32%
3M Horizon AACB +29.83 pp
AACB: +1.92% · NCNA: -27.91%
6M Horizon AACB +66.91 pp
AACB: +3.12% · NCNA: -63.79%
1Y Horizon AACB +58.71 pp
AACB: +3.12% · NCNA: -55.59%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AACB vs NCNA. Trailing 12-month operating profitability (AACB 0.0% vs NCNA 0.0%) and valuation multiples (AACB N/M vs NCNA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AACB ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M
NCNA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-70.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AACB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NCNA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NCNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AACB Moat Profile Cyclical / Execution-Driven Positioning
Shell Companies Operator
Competes within the Shell Companies value chain with $292.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NCNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AACB vs NCNA Key Questions & Quantitative Answers

As of Nov 16, 2026, AACB (AACB) is the stronger overall head-to-head candidate over NuCana plc American Depositary Share (NCNA) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AACB carries a Unified Composite Score of 55.3/100 (HOLD) at $10.59 (N/M Forward P/E, 0.0% operating margin), whereas NCNA carries 43.2/100 (HOLD) at $0.86 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: AACB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 61.7); meanwhile NCNA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AACB and NCNA split Growth & Scale metrics: AACB posts +0.0% YoY revenue growth and -73.2% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NCNA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AACB generates N/A in USD-normalized revenue versus N/A for NCNA. In operating R&D and SG&A reinvestment, AACB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NCNA.

AACB screens cheaper on headline valuation multiples. AACB trades at N/M Forward P/E, 62.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NCNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AACB (0.0% ROE) versus NCNA (-70.3% ROE) capital efficiency.

In options market volatility and institutional positioning, AACB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.02β · 3% Vol realized risk). By comparison, NCNA carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.